Search Results

Next on the Dr. GPCR Podcast, we have Dr. Nicola Smith, Molecular Pharmacologist, lab head, and senior lecturer at UNSW Sydney. Subscribe to the podcast today and get notified when new episodes are released! Please share! https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/ #gpcr #drgpcr #podcast

March 2022 "Congratulations to Richard J. Law, our newly named Chief Business Officer.

of receptor activity-modifying proteins in obesity and diabetes mellitus Maleesha Ubhayarathna , Christopher Langmead , Gregory Stewart , et al. for their fantastic review on Molecular and structural insights into the 5-HT2C receptor as a therapeutic target for substance use disorders Leigh Walker , Christopher Langmead , Andrew Lawrence , et al. for their remarkable analysis on Targeting muscarinic receptors

.; Tuisku, J. M.; Hirvonen, J. E. S.; Vahlberg, T.; Lahdenpohja, S.; Rinne, J. O.; Brück, A. E. J. Med. Der Wel, T.; Mandhair, H.; Honer, M.; Fingerle, J.; Scheffel, J.; Broichhagen, J.; Gawrisch, K.; Romero , J.; Hillard, C. .; Hénichart, J.-P.

.; Boström, J. J. Med. Chem.   2016 , 59  (10), 4443–4458. https://doi.org/10.1021/acs.jmedchem.5b01409 . .; Salvador Andresa, J.; Allongue, P.; Chazalviel, J.-N.; Gouget-Laemmel, A.   (3) Fan, J.; Toth, I.; Stephenson, R. J.

Christopher Langmead and colleagues' work on the 5-HT2C receptor as a therapeutic target for substance

Wouters OJ, McKee M, Luyten J. J Health Econ. 2016;47:20-33. 8.            Lu S, He X, Ni D, Zhang J. Changeux J-P, Christopoulos A. J Phys Chem B. 2016;120(11):2878-85. 36.        

J., Fung, J. J., Pardon, E., Casarosa, P., Chae, P. S., Devree, B. T., Rosenbaum, D. M., Thian, F. H., Pautsch, A., Steyaert, J., Weis, W. I., & Kobilka, B. K. (2011). M., Manglik, A., Hu, J., Hu, K., Eitel, K., Hübner, H., Pardon, E., Valant, C., Sexton, P. C., Gmeiner, P., Steyaert, J., Weis, W. I., Garcia, K. C., Wess, J., & Kobilka, B. K. (2013). Nature, 504(7478), 101–106. https://doi.org/10.1038/nature12735 Burg, J. S., Ingram, J.

Reference   Bikker, J. A., Trumpp-Kallmeyer, S., & Humblet, C. (1998). Carlsson, J., Yoo, L., Gao, Z. G., Irwin, J. J., Shoichet, B. K., & Jacobson, K. A. (2010). T., Baltos, J.-A., Thomas, T., Nguyen, T. D., Muñoz, L. L., Gregory, K. J., White, P. J., Sexton, P. M., Christopoulos, A., & May, L. T. (2016).

Che for their analysis of GPCR-G protein selectivity revealed by structural pharmacology Yao Lu, Drs Christopher Langmead,  Gregory Stewart, et al. for their study on Molecular insights into orphan G protein-coupled

trial Salipro Biotech is attending the 3rd Advanced Therapy Showcase in Tokyo, Japan, organized by LINK-J Christopher Prior, as CEO and Reports Recent Drug Discovery Highlights Call for GPCR Papers GPCRs: Signal

excellent study on Molecular glues as potential GPCR therapeutics Sabrina Rahman , Arthur Christopoulos , Christopher Langmead , et al. for their outstanding work on Ligand-directed biased agonism at human histamine H3

S., Sousa, J. B., Gonçalves, J., & Diniz, C. (2019). N., Castro, M., Wang, B., Bouley, R., Potts, J. T., Gardella, T. J., & Vilardaga, J. P. (2009). J. (2003). J., & Calebiro, D. (2016). J., & Calebiro, D. (2017).

Adapted from: Zhang Y, Tang H, Chen W, Zhang J. Int J Mol Sci. 2022 Aug 3;23(15):8625 . Miranda-Pastoriza D, Bernárdez R, Azuaje J, Prieto-Díaz R, Majellaro M, Tamhankar AV, Koenekoop L, González A, Gioé-Gallo C, Mallo-Abreu A, Brea J, Loza MI, García-Rey A, García-Mera X, Gutiérrez-de-Terán H,

References: Lyu, J. et al. AlphaFold2 structures guide prospective ligand discovery. Science https://doi.org/10.1126/science.adn6354 (2024) Abramson, J., Adler, J., Dunger, J. et al.

Nichola J Smith's investigation: Gene expression of TAS1R taste receptors for cardiometabolic disease Christophe Arbet-Engels to Join as Chief Medical Officer GPCR Events, Meetings, and Webinars ONCORNET2.0

Int J Mol Sci. 2014 Feb 13;15(2):2554-72. Source: Navarro G, Sotelo E, Raïch I, Loza MI, Brea J, Majellaro M. References Navarro G, Sotelo E, Raïch I, Loza MI, Brea J, Majellaro M. Int J Mol Sci. 2014 Feb 13;15(2):2554-72. doi: 10.3390/ijms15022554.

, J. H.; Winkelman, J. , J.; Allen, R. J. J. Med.

J.; Graham, G. J., 2013). J., et al. 2010), which may ultimately compete with receptor antagonists, thereby decreasing the efficacy

antihistamines: A clinical trial is needed Jillian G Baker ,  Erica K Sloan ,   Kevin Pfleger ,  Peter J Trung Duong Nguyen ,  Ziaurrehman Tanoli ,  Saad Hassan , Umut Onur Özcan ,   Jimmy Caroli ,   Albert J physiological ligand complexes Luis P Taracena Herrera , Søren N Andreassen ,   Jimmy Caroli ,   Albert J a human bitter taste GPCR Lior Peri ,  Donna Matzov ,  Dominic R Huxley ,   Peter Gmeiner ,  Peter J

in-depth-molecular-profiling-of-an-intronic-gnao1-mutant-as-the-basis-for-personalized-high-throughput-drug-screening References Grimes, J. M., Medel-Lacruz, B., Baidya, M., Makarova, M., Mistry, R., Goulding, J., Drube, J., Hoffmann, C., Owen K., Selent, J., Hill, S. J., & Calebiro, D. (2023). Cell, 186(10), 2238–2255.e20. https://doi.org/10.1016/j.cell.2023.04.018 Janetzko, J., Kise, R., Barsi-Rhyne

Source: Kim J, Choi C. Cells. 2020 Feb 23;9(2):506. doi: 10.3390/cells9020506   Kim J, Choi C. Oct 19;46(10):11646-11664. doi: 10.3390/cimb46100691   Navarro G, Sotelo E, Raïch I, Loza MI, Brea J,

using the known structure of a homologous protein as a template to model the target protein ( Carlsson, J. References: Carlsson, J.  et al.  

References Barbazán J, Majellaro M, Martínez AL, Brea JM, Sotelo E, Abal M. Br J Pharmacol. 2020 Mar;177(5):978-991. doi: 10.1111/bph.14953. Sridharan R, Zuber J, Connelly SM, Mathew E, Dumont ME.

J. (2019). Volmat, V., & Pouysségur, J. (2001). Spatiotemporal regulation of the p42/p44 MAPK pathway. J. (2003).

Br J Pharmacol. 2023 Dec 12. doi: 10.1111/bph.16297.  Navarro G, Sotelo E, Raïch I, Loza MI, Brea J, Majellaro M.

J., Benovic, J. L., Dohlman, H. G., Frielle, T., Bolanowski, M. A., Bennett, C. J., & Strader, C. D. (1986).

M., Stephany, J. J., & Fields, S. (2014). D., English, J. G., Coyote-Maestas, W., & Aashish Manglik. (2024).

J. B. Nibbs et al. 2013). Paing et al. 2022; J. L. J. Seaman 2012). J. al 2010) which may ultimately compete with receptor antagonists, thereby decreasing the efficacy (J.

Robert J Lefkowitz and team's study 'GPCR signal transduction: β-arrestin activates ERK MAPK.' Dr. J. Silvio Gutkind.